OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunogenicity and Safety of Standard and Third‐Dose SARS –CoV ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 45
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 45
Showing 1-25 of 45 citing articles:
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases
Michelle W. Cheung, Roya M. Dayam, Janna R. Shapiro, et al.
The Journal of Immunology (2023) Vol. 211, Iss. 3, pp. 351-364
Open Access | Times Cited: 23
Michelle W. Cheung, Roya M. Dayam, Janna R. Shapiro, et al.
The Journal of Immunology (2023) Vol. 211, Iss. 3, pp. 351-364
Open Access | Times Cited: 23
Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
Chiara Farroni, Alessandra Aiello, Andrea Picchianti Diamanti, et al.
International Journal of Infectious Diseases (2022) Vol. 125, pp. 195-208
Open Access | Times Cited: 32
Chiara Farroni, Alessandra Aiello, Andrea Picchianti Diamanti, et al.
International Journal of Infectious Diseases (2022) Vol. 125, pp. 195-208
Open Access | Times Cited: 32
Effect of DMARDs on the immunogenicity of vaccines
Yannick van Sleen, Kornelis S. M. van der Geest, Anke Huckriede, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 9, pp. 560-575
Closed Access | Times Cited: 18
Yannick van Sleen, Kornelis S. M. van der Geest, Anke Huckriede, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 9, pp. 560-575
Closed Access | Times Cited: 18
Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
Qian Qiao, Jiachen Sun, Ya Zheng, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Qian Qiao, Jiachen Sun, Ya Zheng, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Impaired Hepatitis B and COVID-19 vaccination responses show strong concordance in hemodialysis patients with end stage renal disease
Karsten Lürken, Anna Meinecke, Luis A. Manthey, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Karsten Lürken, Anna Meinecke, Luis A. Manthey, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002417-e002417
Open Access | Times Cited: 24
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002417-e002417
Open Access | Times Cited: 24
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
Ruth Xian Lynn Yap, Yi Wye Lai, Chang Wei, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 274-274
Open Access | Times Cited: 4
Ruth Xian Lynn Yap, Yi Wye Lai, Chang Wei, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 274-274
Open Access | Times Cited: 4
A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection
Yang Yu, Si Chen, Haonan Zhang, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 4
Open Access | Times Cited: 4
Yang Yu, Si Chen, Haonan Zhang, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 4
Open Access | Times Cited: 4
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
K. H. Bjørlykke, Hilde S Ørbo, Anne Therese Tveter, et al.
The Lancet Rheumatology (2022) Vol. 5, Iss. 1, pp. e36-e46
Open Access | Times Cited: 20
K. H. Bjørlykke, Hilde S Ørbo, Anne Therese Tveter, et al.
The Lancet Rheumatology (2022) Vol. 5, Iss. 1, pp. e36-e46
Open Access | Times Cited: 20
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Hilde S Ørbo, K. H. Bjørlykke, Joseph Sexton, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003545-e003545
Open Access | Times Cited: 3
Hilde S Ørbo, K. H. Bjørlykke, Joseph Sexton, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003545-e003545
Open Access | Times Cited: 3
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination
Elisa Habermann, Lutz Gieselmann, Pinkus Tober‐Lau, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002639-e002639
Open Access | Times Cited: 17
Elisa Habermann, Lutz Gieselmann, Pinkus Tober‐Lau, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002639-e002639
Open Access | Times Cited: 17
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
Clodoveo Ferri, Laura Gragnani, Vincenzo Raimondo, et al.
Journal of Autoimmunity (2022) Vol. 131, pp. 102866-102866
Open Access | Times Cited: 16
Clodoveo Ferri, Laura Gragnani, Vincenzo Raimondo, et al.
Journal of Autoimmunity (2022) Vol. 131, pp. 102866-102866
Open Access | Times Cited: 16
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
Andrea Picchianti Diamanti, Assunta Navarra, Gilda Cuzzi, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 687-687
Open Access | Times Cited: 8
Andrea Picchianti Diamanti, Assunta Navarra, Gilda Cuzzi, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 687-687
Open Access | Times Cited: 8
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series
Inés Colmegna, Valeria Valerio, Nathalie Amiable, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e003400-e003400
Open Access | Times Cited: 8
Inés Colmegna, Valeria Valerio, Nathalie Amiable, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e003400-e003400
Open Access | Times Cited: 8
Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023
Carlos Abud‐Mendoza, Francisco Javier Aceves‐Ávila, César Alejandro Arce-Salinas, et al.
Reumatología Clínica (2024) Vol. 20, Iss. 5, pp. 263-280
Closed Access | Times Cited: 2
Carlos Abud‐Mendoza, Francisco Javier Aceves‐Ávila, César Alejandro Arce-Salinas, et al.
Reumatología Clínica (2024) Vol. 20, Iss. 5, pp. 263-280
Closed Access | Times Cited: 2
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
Ingrid Christensen, Ingrid Jyssum, Anne Therese Tveter, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Ingrid Christensen, Ingrid Jyssum, Anne Therese Tveter, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Vaccination in the Era of Immunosuppression
Fatima Alnaimat, Jaleel Jerry G. Sweis, Jacqueline Jansz, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1446-1446
Open Access | Times Cited: 7
Fatima Alnaimat, Jaleel Jerry G. Sweis, Jacqueline Jansz, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1446-1446
Open Access | Times Cited: 7
Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
Federica Filippini, Mauro Giacomelli, Chiara Bazzani, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 6
Federica Filippini, Mauro Giacomelli, Chiara Bazzani, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 6
Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study
Anne-Marie Svensson, Hanne‐Dorthe Emborg, Lars Erik Bartels, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1359-1367
Closed Access | Times Cited: 6
Anne-Marie Svensson, Hanne‐Dorthe Emborg, Lars Erik Bartels, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1359-1367
Closed Access | Times Cited: 6
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
Zesheng An, Gabriel Figueroa‐Parra, Xian Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Zesheng An, Gabriel Figueroa‐Parra, Xian Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases
Axel Finckh, Adrian Ciurea, Catherine Raptis, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S13-S23
Open Access | Times Cited: 6
Axel Finckh, Adrian Ciurea, Catherine Raptis, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S13-S23
Open Access | Times Cited: 6
Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine
Sara K. Tedeschi, Daniel H. Solomon, Yuezhou Chen, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 59, pp. 152177-152177
Open Access | Times Cited: 5
Sara K. Tedeschi, Daniel H. Solomon, Yuezhou Chen, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 59, pp. 152177-152177
Open Access | Times Cited: 5
Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients
Yusuke Kashiwado, Yasutaka Kimoto, Shiro Ohshima, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 3, pp. 725-733
Closed Access | Times Cited: 5
Yusuke Kashiwado, Yasutaka Kimoto, Shiro Ohshima, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 3, pp. 725-733
Closed Access | Times Cited: 5
